Reported about 1 month ago
Eli Lilly is ramping up its campaign against counterfeit versions of its popular weight-loss drugs, Mounjaro and Zepbound, as it seeks to end a regulatory designation that has allowed cheaper alternatives to thrive in the market. Despite the FDA not confirming an end to supply shortages, Eli Lilly has reported increased availability and is warning healthcare providers to cease compounding the drugs. The rise of compounding pharmacies has created competition, leading Eli Lilly to introduce a more affordable formulation of Zepbound to address demand while ensuring patients receive authentic medications.
Source: YAHOO